The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…
Headline
The Department of Health and Human Services Office of Inspector General yesterday issued an alert warning of marketing schemes by certain Medicare Advantage…
Headline
The AHA's Forever Grateful social media toolkit features posts and graphics expressing support and appreciation for all health care workers. Hospitals and…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
The Office for Civil Rights in the Department of Health and Human Services Dec. 5 issued a letter to health care providers and others clarifying language…
Headline
The Congressional Budget Office Dec. 5 informed Congress that 2.2 million consumers would lose their health insurance in 2026 if enhanced premium subsidies are…